A clinical investigator at Children’s Hospital of Los Angeles, Hisham Abdel-Azim, MD, MS, and colleagues, have completed a study where they engineered T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells rather than just one. This breakthrough could lead to clinical trials to test the therapy.
Acute Lymphoblastic Leukemia (ALL)
Being the most common childhood cancer, most children actually respond to chemotherapy; however, some experience resistant or relapsed disease. CAR-T therapy was developed to bridge the gap for those children for whom chemotherapy wasn’t enough or just didn’t work.
CAR-T Therapy & Limitations with Missing CD-19
This approach uses the patient’s own T-cells, isolating and genetically modifying them to recognize CD-19—a protein (antigen) found on leukemia cells. When the T-cells are introduced back into the patient, the immune system attacks the cancer. Although CAR-T offers meaningful results for many, nearly half of patients who received the therapy later relapsed because the cancer stopped producing the protein CD-19 and became invisible to the T-cells.
‘A Trident instead of a Spear’
Dr. Abdel-Azim and te...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).